0001209191-21-069050.txt : 20211210
0001209191-21-069050.hdr.sgml : 20211210
20211210163250
ACCESSION NUMBER: 0001209191-21-069050
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210831
FILED AS OF DATE: 20211210
DATE AS OF CHANGE: 20211210
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Menzel Garry E
CENTRAL INDEX KEY: 0001556064
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38811
FILM NUMBER: 211485805
MAIL ADDRESS:
STREET 1: C/O REGULUS THERAPEUTICS INC.
STREET 2: 3545 JOHN HOPKINS COURT SUITE 210
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: TCR2 THERAPEUTICS INC.
CENTRAL INDEX KEY: 0001750019
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 474152751
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 100 BINNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 617-949-5200
MAIL ADDRESS:
STREET 1: 100 BINNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-08-31
0
0001750019
TCR2 THERAPEUTICS INC.
TCRR
0001556064
Menzel Garry E
C/O TCR2 THERAPEUTICS
100 BINNEY STREET
CAMBRIDGE
MA
02142
1
1
0
0
President & CEO
Common Stock
84527
I
See Footnote
Common Stock
2021-08-31
5
A
0
E
422
14.26
A
4507
D
Common Stock
2021-12-09
4
M
0
175000
0.74
A
179507
D
Stock Option (Right to Buy)
0.74
2021-12-10
4
M
0
169054
0.74
A
2026-12-12
Common Stock
169054
0
D
Stock Option (Right to Buy)
0.74
2021-12-10
4
M
0
5946
0.74
A
2027-12-06
Common Stock
5946
138031
D
Stock Option (Right to Buy)
5.21
2021-12-09
4
A
0
305800
0.00
A
2031-12-08
Common Stock
305800
305800
D
Consists of 84,527 shares of common stock held by Dr. Garry Menzel, as Trustee of the Garry E. Menzel and Mary E. Henshall Family Trust, under instrument of trust dated July 29, 2010. Dr. Menzel is the trustee of the Garry E. Menzel and Mary E. Henshall Family Trust and may be deemed to beneficially own these securities.
The reporting person is voluntarily reporting the acquisition of shares of the issuer's common stock pursuant to the issuer's 2018 Employee Stock Purchase Plan ("ESPP") for the ESPP purchase period of March 1, 2021 through August 31, 2021. This transaction is exempt under Rule 16b-3(c).
In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on August 31, 2021.
The Reporting Person was granted an option to purchase 253,581 shares on December 13, 2016. 84,527 of such options were previously exercised. 25% of this option vested and became exercisable on October 17, 2017, with the remainder vesting in thirty-six (36) equal monthly installments thereafter.
25% of this option vested and became exercisable on December 6, 2018, with the remainder vesting in thirty-six (36) equal monthly installments thereafter.
25% of this option shall vest and become exercisable on January 1, 2023, with the remainder vesting in thirty-six (36) equal monthly installments thereafter
/s/ Margaret Siegel as Attorney-in-Fact
2021-12-10